[1]方　芳,吴　玲,魏善闯,等.宫颈癌患者血清LCN2水平表达与HPV病毒载量及临床分期的相关研究[J].现代检验医学杂志,2022,37(02):80-84.[doi:10.3969/j.issn.1671-7414.2022.02.017]
　FANG Fang,WU Ling,WEI Shan-chuang,et al.Correlation of Expression of Serum LCN2 Level with HPV Load and Clinical Stage in Patients with Cervical Cancer[J].Journal of Modern Laboratory Medicine,2022,37(02):80-84.[doi:10.3969/j.issn.1671-7414.2022.02.017]
点击复制

宫颈癌患者血清LCN2水平表达与HPV病毒载量及临床分期的相关研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第37卷
期数:
2022年02期
页码:
80-84
栏目:
论　著
出版日期:
2022-03-15

文章信息/Info

Title:
Correlation of Expression of Serum LCN2 Level with HPV Load and Clinical Stage in Patients with Cervical Cancer
文章编号:
1671-7414（2022）02-080-06
作者:
方　芳; 吴　玲; 魏善闯; 胡林义; 张春花
（淮安市妇幼保健院妇科，江苏淮安 223002）
Author(s):
FANG Fang;  WU Ling;  WEI Shan-chuang;  HU Lin-yi;  ZHANG Chun-hua
（Department of Gynecology, Huaian Maternal and Child Health Hospital, Jiangsu Huaian 223002, China）
关键词:
宫颈癌; 脂质运载蛋白2; 高危型人乳头瘤病毒载量
分类号:
R737.33；R730.43
DOI:
10.3969/j.issn.1671-7414.2022.02.017
文献标志码:
A
摘要:
目的　探究宫颈癌患者血清脂质运载蛋白2（lipocalin 2，LCN2）水平，分析其与高危型人乳头瘤病毒（high risk-human papilloma virus，HR-HPV）病毒载量及临床分期的相关性。方法　选取2019 年4 月～ 2021 年2 月淮安市妇幼保健院收治的宫颈癌患者64 例为研究对象（宫颈癌组），另选取同期治疗的宫颈上皮内瘤变患者60 例（宫颈上皮内瘤变组）和体检健康女性69 例（正常对照组）。采用第二代杂交捕获技术（hybrid capture Ⅱ，HC- Ⅱ）进行HRHPV病毒载量检测，采用酶联免疫吸附试验（enzyme-linked immunosorbent assay，ELISA）法检测血清LCN2 水平，采用Pearson 法分析宫颈上皮内瘤变和宫颈癌患者HR-HPV 病毒载量与血清LCN2 水平相关性；采用受试者工作特征（receiver operating characteristic，ROC）曲线分析HR-HPV 病毒载量与血清LCN2 水平对宫颈癌的诊断效能。结果　宫颈癌组、宫颈上皮内瘤变组、正常对照组HR-HPV 病毒载量（1 173.51±264.37，669.61±123.92，0.52±0.15RLU/CO）及血清LCN2 水平（84.16±26.95，43.67±13.82，12.05±4.31pg/ml）依次降低，差异有统计学意义（F=825.576，282.028，均P =0.000）。宫颈上皮内瘤变及宫颈癌患者HR-HPV 病毒载量与血清LCN2 水平均呈正相关（r=0.386，P=0.002；r=0.375，P=0.003）。HR-HPV 病毒载量与血清LCN2 水平联合检测对宫颈癌诊断的曲线下面积为0.872（95%CI：0.790~0.928），敏感度和特异度分别为90.19% 和83.00%。FIGO 分期Ⅰ，Ⅱ和Ⅲ期患者HR-HPV 病毒载量（1 018.82±101.27，1 181.64±124.73，1 294.37±113.06RLU/CO）及血清LCN2 水平（66.55±10.18，85.05±15.66，98.04±13.07 ）pg/ml 依次明显升高，差异有统计学意义（F=28.574，29.060，均P =0.000）；脉管浸润阳性、淋巴结转移患者HR-HPV 病毒载量（1 293.51±113.17，1 294.37±113.06RLU/CO） 及血清LCN2 水平（97.31±18.63，98.04±13.07）pg/ml 明显高于脉管浸润阴性（1 101.05±139.84RLU/CO，76.27±12.06pg/ml）和无淋巴结转移患者（1129.23±117.51RLU/CO, 79.14±14.27pg/ml），差异均有统计学意义（F=5.851，4.619，3.927，3.722，均P =0.000）。结论　宫颈癌患者血清LCN2 水平明显升高，与HR-HPV 病毒载量升高、FIGO 分期升高、脉管浸润及淋巴结转移等进展有关，可能作为标志物预示宫颈癌的发生发展。
Abstract:
Objective　To investigate the expression level of serum lipocalin 2 (LCN2) in patients with cervical cancer, and analyze the correlation between LCN2 and the viral load, clinical stage of high risk-human papilloma virus (HR-HPV). Methods　From April 2019 to February 2021, 64 patients with cervical cancer in Huaian Maternal and Child Health Hospital were selected as the study objects (cervical cancer group). In addition, 60 cases of cervical intraepithelial neoplasia treatedin the hospital at the same time (cervical intraepithelial neoplasia group) and 69 healthy women (normal control group) were selected. The second generation hybrid capture Ⅱ (HC- Ⅱ ) was used to detect the viral load of HR-HPV, the expression level of serum LCN2 was detected by enzyme-linked immunosorbent assay (ELISA). Pearson method was used to analyze the correlation between HR-HPV load and serum LCN2 level in patients with cervical intraepithelial neoplasia and cervical cancer. In addition, receiver operating characteristic (ROC) curve was used to analyze the diagnostic efficacy of HR-HPV viral load and serum LCN2 level for cervical cancer. Results　HR-HPV viral load (1173.51±264.37, 669.61±123.92, 0.52±0.15 RLU/CO) and serum LCN2 level (84.16±26.95, 43.67±13.82, 12.05±4.31 pg/ml) in cervical cancer group, cervical intraepithelial neoplasia group and normal control group decreased in turn, the differences were statistically significant (F=825.576, 282.028, all P=0.000). There was a positive correlation between HR-HPV viral load and serum LCN2 level in cervical intraepithelial neoplasia and cervical cancer (r=0.386, P=0.002; r=0.375, P=0.003). The area under the curve of HR-HPV viral load combined with serum LCN2 level in the diagnosis of cervical cancer was 0.872 (95% CI: 0.790 ～ 0.928), the sensitivity and the specificity were 90.19% and 83.00%, respectively. The HR-HPV viral load (1 018.82±101.27, 1 181.64±124.73, 1 294.37±113.06RLU/CO) and serum LCN2 level (66.55±10.18, 85.05±15.66, 98.04±13.07 pg/ml) in patients with FIGO stage I, II and III were significantly increased in turn， the differences were statistically significant (F=28.574, 29.060, all P=0.000). The HR-HPV viral load and serum LCN2 level in patients with positive vessel infiltration (1 293.51±113.17, 1 294.37±113.06 RLU/CO) and lymph node metastasis (97.31±18.63, 98.04±13.07pg/ml) were significantly higher than those in patients with negative vessel infiltration (1 101.05±139.84 RLU/CO, 76.27±12.06pg/ml) and non lymph node metastasis (1 129.23±117.51 RLU/CO, 79.14±14.27pg/ ml), the differences were statistically significant (F=5.851, 4.619, 3.927, 3.722, all P=0.000). Conclusion　The level of serum LCN2 in patients with cervical cancer was significantly higher, which was related to the increase of HR-HPV viral load, the increase of FIGO stage, vascular invasion, lymph node metastasis and so on. It may be used as a marker to predict the occurrence and development of cervical cancer.

参考文献/References:

[1] 任思颖, 秦明芳, 陈杨, 等．云南省肿瘤登记地区 2011-2015 年宫颈癌发病和死亡特征及时间趋势[J]. 实用肿瘤学杂志, 2021, 35(1):13-17. REN Siying, QIN Mingfang, CHEN Yang, et al. Characteristics and time trend of incidence and death of cervical cancer from 2011 to 2015 in cancer registration area of Yunnan province [J]. Practical Oncology Journal, 2021, 35(1):13-17.
[2] 高红敏, 杨红英, 刘鑫．血清中microRNA-106b 对 宫颈癌患者的早期诊断及预后预测价值[J]. 现代检 验医学杂志, 2020, 35(6):85-86, 182. GAO Hongmin, YANG Hongying, LIU Xin. Value analysis of serum microRNA-106b in early diagnosis of cervical cancer [J]. Journal of Modern Laboratory Medicine, 2020, 35(6):85-86, 182.
[3] CAO Meng, WANG Ying, WANG Depu, et al. Increased high-risk human papillomavirus viral load is associated with immunosuppressed microenvironment and predicts a worse long-term survival in cervical cancer patients[J].American Journal of Clinical Pathology, 2020, 153(4): 502-512.
[4] ZHAO Hui, DING Feng, ZHENG Guanghong. LncRNA TMPO-AS1 promotes LCN2 transcriptional activity and exerts oncogenic functions in ovarian cancer[J]. FASEB Journal, 2020, 34(9): 11382-11394.
[5] SANTIAGO-S?NCHEZ GS, PITA-GRISANTI V, QUI?ONES-D?AZ B, et al. Biological functions and therapeutic potential of lipocalin 2 in cancer[J]. International Journal of Molecular Sciences, 2020, 21(12): 4365.
[6] 李静, 索红燕, 孔为民《. 国际妇产科联盟(FIGO)2018 癌症报告: 宫颈癌新分期及诊治指南》解读[J]. 中 国临床医生杂志, 2019, 47(6):646-649. LI Jing, SUO Hongyan, KONG Weimin. Interpretation of the 2018 cancer report of the international federation of obstetrics and gynecology (FIGO): A new stage and guidance for diagnosis and treatment of cervical cancer[J]. Chinese Journal for Clinicians, 2019, 47(6):646-649.
[7] 谢春, 朱海东. 高危型HPV 病毒载量与宫颈癌 及癌前分型的相关性分析[J]. 重庆医学, 2018, 47(9):1287-1289． XIE Chun, ZHU Haidong. Correlation analysis of high-risk HPV viral load with cervical cancer and precancerous typing[J]. Chongqing Medicine, 2018, 47(9): 1287-1289.
[8] PA?CZYSZYN A, BONIEWSKA-BERNACKA E, G??B G. Telomere length in leukocytes and cervical smears of women with high-risk human papillomavirus (HR HPV) infection[J]. Taiwanese Journal of Obstetrics & Gynecology, 2020, 59(1): 51-55.
[9] 张赛男, 王观凤, 郑丽娇, 等.hPygo2 在宫颈癌中表 达及其与HR-HPV 感染的相关性研究[J]. 现代妇产 科进展, 2018, 27(5):348-350. ZHANG Sainan, WANG Guanfeng, ZHENG Lijiao, et al. Expression of hPygo2 in cervical intraepithelial neoplasia and cervical cancer and their rela-tionship to viral load of high-risk human papillomavirus[J]. Progress in Obstetrics and Gynecology, 2018, 27(5):348-350.
[10] ERNSTSON A, URDELL A, FORSLUND O, et al. Cervical cancer prevention among long-term screening non-attendees by vaginal self-collected samples for hr-HPV mRNA detection[J]. Infectious Agents and Cancer, 2020, 15(1): 10.
[11] MANE A, PATIL L, LIMAYE S, et al. Characterization of major capsid protein (L1) variants of human papillomavirus type 16 by cervical neoplastic status in Indian women: Phylogenetic and functional analysis[J]. Journal of Medical Virology, 2020, 92(8): 1303-1308.
[12] FAN Qiong, HUANG Ting, SUN Xiao, et al. HPV-16/18 E6-induced APOBEC3B expression associates with proliferation of cervical cancer cells and hypomethylation of Cyclin D1[J]. Molecular Carcinogenesis, 2021, 60(5): 313-330.
[13] WANG Wei, ZHANG Xianhui, LI Mei, et al. Association between viral loads of different oncogenic human papillomavirus types and the degree of cervical lesions in the progression of cervical cancer[J]. Clinica Chimica Acta, 2018, 483(1): 249-255.
[14] SIEGLER E, REICHMAN Y, KUGELMAN N, et al. Low-risk human papillomavirus types in cervical intraepithelial neoplasia 2-3 and in invasive cervical cancer patients[J]. Journal of Lower Genital Tract Disease, 2019, 23(4): 248-252.
[15] CELEGATO M, MESSA L, GORACCI L, et al. A novel small-molecule inhibitor of the human papillomavirus E6-p53 interaction that reactivates p53 function and blocks cancer cells growth[J]. Cancer Letters, 2020, 470(1): 115-125.
[16] CHEN Lihua, DONG Binhua, ZHANG Qiaoyu, et al. HR-HPV viral load quality detection provide more accurate prediction for residual lesions after treatment: a prospective cohort study in patients with high-grade squamous lesions or worse[J]. Medical Oncology (Northwood, London, England), 2020, 37(5): 37.
[17] 邱淑佳. 慢性阻塞性肺疾病患者血清LCN1 和 LCN2 的表达水平及临床意义[J]. 现代检验医学杂 志, 2017, 32(6):67-70, 73. QIU Shujia. Expression levels of serum LCN1 and LCN2 in patients with acute exacerbation of chronic obstructive pulmonary disease and its clinical significance [J]. Journal of Modern Laboratory Medicine, 2017, 32(6):67-70, 73.
[18] LU Yongming, DONG Baijun, XU Fan, et al. CXCL1- LCN2 paracrine axis promotes progression of prostate cancer via the Src activation and epithelialmesenchymal transition [J]. Cell Communication and Signaling : CCS, 2019, 17(1): 118.
[19] 毕泗成, 刘浩, 张鹏, 等. 血清LCN2 与PSA 联合 检测对前列腺癌的诊断价值[J]. 国际肿瘤学杂志, 2018, 45(1):27-31. BI Sicheng, LIU Hao, ZHANG Peng, et al. Diagnostic value of serum lipocalin 2 combined with prostatespecific antigen in prostate cancer [J].Journal of International Oncology, 2018, 45(1): 27-31.
[20] KUROZUMI S, ALSAEED S, ORAH N, et al. Clinicopathological significance of lipocalin 2 nuclear expression in invasive breast cancer[J]. Breast Cancer Research and Treatment, 2020, 179(3): 557-564.
[21] XU Hua, SUN Xing, SUN Wenjun. Expression and clinical correlation of NGAL and VEGF in endometrial carcinoma[J]. European Review for Medical and Pharmacological Sciences, 2018, 22(3): 632-636.
[22] BOGORODSKAYA M, FITCH K V, BURDO T H,et al. Serum lipocalin 2 (neutrophil gelatinaseassociated lipocalin) in relation to biomarkers of inflammation and cardiac stretch during activation of the renin-angiotensin-aldosterone system in human immunodeficiency virus [J]. Journal of Infectious Diseases, 2019, 220(9): 1420-1424.
[23] VITKAUSKAIT? A, CELIE?I?T? J, PA?KAUSKAS S, et al. Associations among serum lipocalin-2 concentration, human papilloma virus and clinical stage of cervical cancer [J]. Medicina (Kaunas, Lithuania), 2019, 55(6): 229.

相似文献/References:

[1]田英,王双勇,赵雅,等.宫颈癌组织细胞中Numb基因表达及相关性研究[J].现代检验医学杂志,2015,30(06):42.[doi:10.3969/j.issn.1671-7414.2015.06.012]
　TIAN Ying,WANG Shuang-yong,ZHAO Ya,et al.Study on Correlation and Expression of Numb Gene in Cervical Cancer[J].Journal of Modern Laboratory Medicine,2015,30(02):42.[doi:10.3969/j.issn.1671-7414.2015.06.012]
[2]顾益凤,朱自力,史跃燕,等.血浆硫氧还蛋白还原酶水平检测对宫颈癌早期诊断的价值研究[J].现代检验医学杂志,2019,34(02):40.[doi:10.3969/j.issn.1671-7414.2019.02.011]
　GU Yi-feng,ZHU Zi-li,SHI Yue-yan,et al.Study on the Value of Plasma Thioredoxin Reductase Levelin the Early Diagnosis of Cervical Cancer[J].Journal of Modern Laboratory Medicine,2019,34(02):40.[doi:10.3969/j.issn.1671-7414.2019.02.011]
[3]陈 慎,杜明君,宋雅琴.宫颈组织HPV DNA与血清Chemerin,Leptin水平联合检测对宫颈癌早期诊断的价值分析[J].现代检验医学杂志,2019,34(03):42.[doi:10.3969/j.issn.1671-7414.2019.03.010]
　CHEN Shen,DU Ming-jun,SONG Ya-qin.Value of Combined Detection of HPV DNA and Serum Levelsof Chemerin and Leptin in Early Diagnosis of Cervical Cancer[J].Journal of Modern Laboratory Medicine,2019,34(02):42.[doi:10.3969/j.issn.1671-7414.2019.03.010]
[4]周　静,李　智,周　玉,等.宫颈癌组织中 Ep-CAM和 Ki67的表达及临床意义[J].现代检验医学杂志,2019,34(06):24.[doi:10.3969 ／ j.issn.1671-7414.2019.06.006]
　ZHOU Jing,LI Zhi,ZHOU Yu,et al.Expression and Clinicd Value of Ep-CAM and Ki67 in the Cervial Carcinoma Tissue[J].Journal of Modern Laboratory Medicine,2019,34(02):24.[doi:10.3969 ／ j.issn.1671-7414.2019.06.006]
[5]徐晓锋a,王　纯b,卢国丰a,等.宫颈癌患者 Kruppel 样因子 6，p21 蛋白表达水平与病理特征及化疗敏感性的相关性分析[J].现代检验医学杂志,2020,35(06):12.[doi:doi:10.3969/j.issn.1671-7414.2020.06.004]
　XU Xiao-feng a,WANG Chun b,LU Guo-feng a,et al.Correlation Analysis of KLF6 and p21 Protein Expression Levels andPathological Features and Chemotherapy Sensitivity in Patientswith Cervical Cancer[J].Journal of Modern Laboratory Medicine,2020,35(02):12.[doi:doi:10.3969/j.issn.1671-7414.2020.06.004]
[6]高红敏,杨红英,刘　鑫.血清中 microRNA-106b 对宫颈癌患者的早期诊断及预后预测价值[J].现代检验医学杂志,2020,35(06):85.[doi:doi:10.3969/j.issn.1671-7414.2020.06.020]
　GAO Hong-min,YANG Hong-ying,LIU Xin.Value Analysis of Serum microRNA-106b in Early Diagnosis ofCervical Cancer[J].Journal of Modern Laboratory Medicine,2020,35(02):85.[doi:doi:10.3969/j.issn.1671-7414.2020.06.020]
[7]赵白信,于慧娟,焦方杰,等.经阴道彩色多普勒超声联合血清 miR-130a，miR-425-5p 水平检测对宫颈癌的诊断效能分析[J].现代检验医学杂志,2021,36(03):43.[doi:10.3969/j.issn.1671-7414.2021.03.010]
　ZHAO Bai-xin,YU Hui-juan,JIAO Fang-jie,et al.Analysis of Diagnostic Efficacy of Transvaginal Color Doppler UltrasoundCombined with Serum miR-130a and miR-425-5p Levels in Cervical Cancer[J].Journal of Modern Laboratory Medicine,2021,36(02):43.[doi:10.3969/j.issn.1671-7414.2021.03.010]
[8]张治洋,李功娟.10株宫颈癌细胞系中MALAT1的表达及其对顺铂敏感性的影响[J].现代检验医学杂志,2021,36(05):110.[doi:10.3969/j.issn.1671-7414.2021.05.024]
　ZHANG Zhi-yang,LI Gong-juan.Expression of MALAT1 in 10 Cervical Cancer Cell Lines and Its Effect onCisplatin Sensitivity[J].Journal of Modern Laboratory Medicine,2021,36(02):110.[doi:10.3969/j.issn.1671-7414.2021.05.024]
[9]郝艳芳,刘亚荣,黄玲玲,等.miRNA-195靶向调控 CCND2和 MYB抑制宫颈癌细胞增殖、迁移的机制研究[J].现代检验医学杂志,2022,37(01):130.[doi:10.3969/j.issn.1671-7414.2022.01.026]
　HAO Yan-fang,LIU Ya-rong,HUANG Ling-ling,et al.Study on the Mechanism of miRNA-195 Targeting CCND2 and MYB to Inhibit the Proliferation and Migration of Cervical Cancer Cells[J].Journal of Modern Laboratory Medicine,2022,37(02):130.[doi:10.3969/j.issn.1671-7414.2022.01.026]
[10]谌媛媛,李 静.宫颈脱落细胞中PAX1 和SOX1 基因甲基化对宫颈癌实验诊断的临床研究[J].现代检验医学杂志,2022,37(06):46.[doi:10.3969/j.issn.1671-7414.2022.06.009]
　CHEN Yuan-yuan,LI Jing.Clinical Study of PAX1 and SOX1 Gene Methylation in Cervical Exfoliated Cells for Experimental Diagnosis of Cervical Cancer[J].Journal of Modern Laboratory Medicine,2022,37(02):46.[doi:10.3969/j.issn.1671-7414.2022.06.009]

备注/Memo

备注/Memo:
基金项目：江苏省妇幼健康重点学科与建设项目（编号FXK201762）；江苏省妇幼健康重点人才、青年人才项目（编号FRC201728）。
作者简介：方芳（1982-），女，本科，副主任医师，研究方向：妇科肿瘤，E-mail：fangfang2659@163.com。
通讯作者：张春花（1977-），女，硕士，副主任医师，研究方向：妇科肿瘤，E-mail：hafyzch@126.com。
更新日期/Last Update: 1900-01-01